Over 4,000 cases. Nearly 1,800 deaths. The DRC Ebola outbreak caused by the rarer Bundibugyo strain is now the second-largest in history — and WHO and Africa CDC are studying whether the virus is changing.
▶ Watch the Short on YouTube
Infectious Diseases in Focus →The Ebola outbreak currently unfolding in the Democratic Republic of the Congo is unlike most of what has come before. In speed, in scale, and in the clinical behavior of the strain involved, it is demanding a level of response and scientific scrutiny that is unusual even in the context of Ebola, a disease long recognized as one of the most dangerous infectious agents on earth.
Cases in the DRC have surpassed 4,000, with nearly 1,800 deaths — a case fatality rate consistent with severe Ebola disease. The outbreak is now the second-largest in the history of recorded Ebola outbreaks, behind only the devastating 2013–2016 West Africa epidemic that killed more than 11,000 people across Guinea, Sierra Leone, and Liberia.
What makes this outbreak scientifically significant beyond its scale is the strain involved. This is not the more familiar Zaire ebolavirus — the strain responsible for the 2013–2016 epidemic and the 2018–2020 DRC outbreaks, and the one for which licensed vaccines and treatments have been developed. This is Bundibugyo ebolavirus — a distinct species first identified in Uganda in 2007 and responsible for only a handful of outbreaks since.
Bundibugyo ebolavirus is one of six recognized species within the genus Ebolavirus. It is genetically and clinically distinct from Zaire ebolavirus. When it was first characterized after the 2007 Uganda outbreak, studies showed it produced a somewhat different clinical picture — including differences in the hemorrhagic features and, importantly, a lower case fatality rate than Zaire ebolavirus in that initial outbreak, estimated at approximately 25–36% compared with the 50–90% historically associated with Zaire.
Ebola does not spread through casual contact or through the air. It spreads through direct contact with the body fluids — blood, saliva, vomit, urine, feces, semen — of a person who is symptomatic or who has died from the disease. This is why healthcare workers, family caregivers, and those involved in traditional burial practices are at highest risk.
Early supportive care also saves lives. There is no fully curative treatment for Bundibugyo ebolavirus, but maintaining fluid balance, electrolytes, and blood pressure — and identifying and treating secondary infections — significantly improves survival, particularly if intervention comes before the later hemorrhagic phase.
This is a serious outbreak that demands serious attention. The scale alone — second-largest in history — would warrant global focus. The addition of a distinct, less-studied strain, the possibility of mutation, and the limited applicability of existing vaccines and treatments creates a more complex response environment than previous major outbreaks.
Health teams from the DRC Ministry of Health, WHO, Africa CDC, and international partners are responding. The response involves science, logistics, community trust, and political will in equal measure. Whether it succeeds will depend on all four.
Staying informed, supporting the organizations working on the ground, and not amplifying unverified information about mutation or spread are the most useful things those outside the region can do right now.